ATE504599T1 - Zur aktivierung von rezeptoren fähige fusionspolypeptide - Google Patents

Zur aktivierung von rezeptoren fähige fusionspolypeptide

Info

Publication number
ATE504599T1
ATE504599T1 AT05711471T AT05711471T ATE504599T1 AT E504599 T1 ATE504599 T1 AT E504599T1 AT 05711471 T AT05711471 T AT 05711471T AT 05711471 T AT05711471 T AT 05711471T AT E504599 T1 ATE504599 T1 AT E504599T1
Authority
AT
Austria
Prior art keywords
fusion polypeptides
polypeptides capable
activating receptors
target receptor
binding
Prior art date
Application number
AT05711471T
Other languages
English (en)
Inventor
James Fandl
Gang Chen
Nicholas Papadopoulos
Thomas Aldrich
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of ATE504599T1 publication Critical patent/ATE504599T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT05711471T 2004-01-16 2005-01-14 Zur aktivierung von rezeptoren fähige fusionspolypeptide ATE504599T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53696804P 2004-01-16 2004-01-16
PCT/US2005/001246 WO2005070966A2 (en) 2004-01-16 2005-01-14 Fusion polypeptides capable of activating receptors

Publications (1)

Publication Number Publication Date
ATE504599T1 true ATE504599T1 (de) 2011-04-15

Family

ID=34807067

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05711471T ATE504599T1 (de) 2004-01-16 2005-01-14 Zur aktivierung von rezeptoren fähige fusionspolypeptide

Country Status (10)

Country Link
US (1) US7534604B2 (de)
EP (1) EP1709081B1 (de)
JP (3) JP4906094B2 (de)
AT (1) ATE504599T1 (de)
AU (1) AU2005206536B2 (de)
CA (1) CA2550551C (de)
DE (1) DE602005027309D1 (de)
DK (1) DK1709081T3 (de)
ES (1) ES2364147T3 (de)
WO (1) WO2005070966A2 (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
CA2447851C (en) * 2001-06-28 2012-08-28 Domantis Limited Dual-specific ligand and its use
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
EP1517921B1 (de) * 2002-06-28 2006-06-07 Domantis Limited Dual-specifische liganden mit erhöhter halbwertszeit
EP1578801A2 (de) * 2002-12-27 2005-09-28 Domantis Limited Dual-spezifischer einzeldomäne-antikörper welcher spezifisch ist für einen liganden und dessen rezeptor
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
EP4353819A3 (de) * 2004-07-22 2024-07-17 Erasmus University Medical Center Rotterdam Bindungsmoleküle
KR20130105885A (ko) 2005-01-05 2013-09-26 에프-스타 비오테크놀로기쉐 포르슝스 운드 엔트비클룽스게스.엠.베.하. 상보성 결정부위와 다른 분자의 부위에서 처리된 결합성을 갖는 합성 면역글로불린 영역
ES2460517T3 (es) 2005-07-25 2014-05-13 Emergent Product Development Seattle, Llc Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20
CN101454344A (zh) * 2005-12-01 2009-06-10 杜门蒂斯有限公司 与白细胞介素-1受体1型结合的非竞争性域抗体形式
US20070264687A1 (en) * 2005-12-15 2007-11-15 Min-Yuan Chou Recombinant triplex scaffold-based polypeptides
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
JP5167155B2 (ja) * 2006-03-09 2013-03-21 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ペプチド結合に基づく多数の細胞株のプロファイリングに関連した組成物および方法
EP2418223A3 (de) * 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Einkettige, multivalente Bindungsproteine mit Effektorfunktion
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
WO2008149147A2 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
ES2627223T3 (es) 2007-06-26 2017-07-27 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Presentación de agentes de unión
WO2009018386A1 (en) * 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
SG189769A1 (en) 2008-01-03 2013-05-31 Scripps Research Inst Antibody targeting through a modular recognition domain
CN101970496B (zh) 2008-03-14 2014-04-16 特朗斯吉有限公司 针对csf-1r的抗体
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
EP2113255A1 (de) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Zytotoxisches Immunglobulin
WO2010066836A2 (en) * 2008-12-10 2010-06-17 Ablynx Nv Amino acid sequences directed against the angiopoietin/tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
WO2011072204A1 (en) 2009-12-10 2011-06-16 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
KR101688522B1 (ko) * 2009-12-15 2016-12-21 삼성전자주식회사 안지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도
SG181952A1 (en) * 2009-12-29 2012-07-30 Emergent Product Dev Seattle Heterodimer binding proteins and uses thereof
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US10143186B2 (en) 2010-02-08 2018-12-04 Regeneron Pharmaceuticals, Inc. Common light chain mouse
WO2011159847A2 (en) 2010-06-15 2011-12-22 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
EP2420253A1 (de) * 2010-08-20 2012-02-22 Leadartis, S.L. Manipulation multifunktioneller und multivalenter Moleküle mit Kollagen-XV-Trimerisationsdomäne
EP3252076B1 (de) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostische verwendung von antikörpern gegen das protein ror-1
EP2714738B1 (de) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalente und monovalente multispezifische komplexe und ihre verwendungen
HRP20192255T1 (hr) 2011-08-05 2020-03-06 Regeneron Pharmaceuticals, Inc. Humanizirani miševi s univerzalnim lakim lancem
NZ629178A (en) * 2012-02-29 2016-09-30 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
JP6628966B2 (ja) 2012-06-14 2020-01-15 中外製薬株式会社 改変されたＦｃ領域を含む抗原結合分子
US9758591B2 (en) 2012-08-24 2017-09-12 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
EP3424530A1 (de) 2013-03-15 2019-01-09 Zyngenia, Inc. Multivalente und monovalente multispezifische komplexe und deren verwendungen
WO2014141192A1 (en) 2013-03-15 2014-09-18 Erasmus University Medical Center Generation of heavy chain-only antibodies
CN111606998B (zh) 2013-09-16 2024-05-24 健康与环境慕尼黑德国研究中心赫姆霍茨中心（有限责任公司） 用于治疗hbv感染和相关病症的双或多特异性多肽
CN105940107B (zh) * 2013-11-11 2021-06-15 中外制药株式会社 含有改变了抗体可变区的抗原结合分子
SG10201808225TA (en) 2014-03-21 2018-10-30 Regeneron Pharma Non-human animals that make single domain binding proteins
TWI742423B (zh) 2014-05-29 2021-10-11 美商宏觀基因股份有限公司 特異性結合多種癌症抗原的三特異性結合分子和其使用方法
WO2015197582A1 (en) * 2014-06-27 2015-12-30 Innate Pharma Monomeric multispecific antigen binding proteins
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
WO2016044745A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
TWI740809B (zh) 2014-11-11 2021-10-01 日商中外製藥股份有限公司 包含經改變之抗體可變區之抗原結合分子的資料庫
AU2015380455A1 (en) 2015-01-26 2017-08-03 Macrogenics, Inc. Multivalent molecules comprising DR5-binding domains
HK1250038A1 (zh) 2015-03-19 2018-11-23 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
HUE055207T2 (hu) 2015-07-30 2021-11-29 Macrogenics Inc PD-1 és LAG-3 kötõ molekulák és eljárások azok alkalmazására
MX2018003292A (es) 2015-09-21 2018-08-01 Aptevo Res & Development Llc Polipéptidos de unión a cd3.
CN108136010A (zh) 2015-10-08 2018-06-08 宏观基因有限公司 用于治疗癌症的联合疗法
EA201891178A1 (ru) 2015-12-14 2019-01-31 Макродженикс, Инк. Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
UY37127A (es) 2016-02-17 2017-08-31 Macrogenics Inc Moléculas de unión a ror1, y métodos de uso de las mismas
TWI781098B (zh) 2016-04-15 2022-10-21 美商宏觀基因股份有限公司 新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法
MX2018016330A (es) 2016-06-27 2020-02-17 Univ California Combinaciones para tratamiento del cáncer.
US11242402B2 (en) 2016-12-23 2022-02-08 Macrogenics, Inc. ADAM9-binding molecules, and methods of use thereof
SG11201907753TA (en) 2017-02-24 2019-09-27 Macrogenics Inc Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
EP3720963A4 (de) 2017-12-05 2021-12-08 Chugai Seiyaku Kabushiki Kaisha Antigen-bindendes molekül mit veränderter bindung der variablen antikörper-regionen cd3 und cd137
WO2019118266A1 (en) 2017-12-12 2019-06-20 Macrogenics Inc. Bispecific cd 16-binding molecules and their use in the treatment of disease
WO2019160904A1 (en) 2018-02-15 2019-08-22 Macrogenics, Inc. Variant cd3-binding domains and their use in combination therapies for the treatment of disease
CN113286824A (zh) 2018-08-03 2021-08-20 中外制药株式会社 包含两个彼此连接的抗原结合结构域的抗原结合分子
EP3856789A4 (de) 2018-09-28 2022-08-17 Chugai Seiyaku Kabushiki Kaisha Antigen-bindendes molekül mit variabler region eines veränderten antikörpers
BR112022013589A2 (pt) 2020-01-08 2022-09-13 Regeneron Pharma Tratamento da fibrodisplasia ossificante progressiva
CA3170330A1 (en) 2020-02-21 2021-08-26 Macrogenics, Inc. Cd137 binding molecules and uses thereof
TWI799824B (zh) 2020-03-31 2023-04-21 日商中外製藥股份有限公司 Ｄｌｌ３靶向之多特異性抗原結合分子及其用途
EP4175650A1 (de) 2020-07-06 2023-05-10 Kiromic BioPharma, Inc. Mesothelinisoformbindende moleküle und chimäre pd1-rezeptormoleküle, zellen damit und verwendungen davon
CA3202233A1 (en) 2020-11-18 2022-05-27 Kiromic BioPharma, Inc. Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955291A (en) * 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
US5747033A (en) * 1993-10-28 1998-05-05 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of Eph family ligands
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
JP2004511430A (ja) * 2000-05-24 2004-04-15 イムクローン　システムズ　インコーポレイティド 二重特異性免疫グロブリン様抗原結合蛋白および製造方法
US20040023880A1 (en) 2002-05-03 2004-02-05 Gale Nicholas W. Methods of inducing formation of functional and organized lymphatic vessels

Also Published As

Publication number Publication date
WO2005070966A2 (en) 2005-08-04
WO2005070966A3 (en) 2005-12-15
DK1709081T3 (da) 2011-06-06
AU2005206536B2 (en) 2010-09-02
US20050158829A1 (en) 2005-07-21
US7534604B2 (en) 2009-05-19
JP2012040024A (ja) 2012-03-01
JP2007536912A (ja) 2007-12-20
EP1709081B1 (de) 2011-04-06
ES2364147T3 (es) 2011-08-25
CA2550551A1 (en) 2005-08-04
JP5383780B2 (ja) 2014-01-08
AU2005206536A1 (en) 2005-08-04
JP4906094B2 (ja) 2012-03-28
DE602005027309D1 (de) 2011-05-19
CA2550551C (en) 2013-10-29
JP2013031462A (ja) 2013-02-14
EP1709081A2 (de) 2006-10-11

Similar Documents

Publication Publication Date Title
ATE504599T1 (de) Zur aktivierung von rezeptoren fähige fusionspolypeptide
CY1116863T1 (el) Πρωτεϊνη δεσμευσης υποδοχεα nogo
WO2004065416A3 (en) Synthetic antibody phage libraries
DE60239097D1 (de) Drei-hybrid-assaysystem
MX2008013057A (es) Proteinas de enlace que comprenden regiones bisagra y regiones fc de inmunoglobulina que tienen funciones efectoras fc alteradas.
EA200700210A1 (ru) ВАРИАНТЫ ОБЛАСТИ Fc
DE69932813D1 (de) Nukleinsäurebindungsproteine
BR0313331A (pt) antagonistas de receptor de nogo
DK1534830T3 (da) In vito-peptid-ekspressionsbibliotek
WO2007136778A3 (en) Fusion proteins, uses thereof and processes for producing same
IS8339A (is) Mótlyf viðtaka NOGO
DE60332711D1 (de) Neue insektizide proteine von bazillus thuringiensis
DE602005019495D1 (de) Ligand für den Formylpeptidrezeptorähnlichen- 2 (FPRL2) G Protein gekoppelten Rezeptor und dessen Anwendung
WO2005087811A3 (en) Estrogen receptors and methods of use
WO2005028664A3 (en) Modulation of programmed necrosis
WO2004090103A8 (en) Identification of novel nogo-receptors and methods related thereto
WO2006046042A3 (en) Method of selecting polypeptides

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties